AbbVie (ABBV) leaned heavily on immunology drugs in the second quarter, helping offset declines for its biggest blood cancer medicine and several aesthetic treatments. But AbbVie stock fell early Frid...
AbbVie (ABBV) leaned heavily on immunology drugs in the second quarter, helping offset declines for its biggest blood cancer medicine and several aesthetic treatments. But AbbVie stock fell early Frid...